SCHEMBL20179211

SCHEMBL20179211

CC(C)(C)CNC(=O)ONC(=O)CCC(Cc1ccc(C(=O)OC(C)(C)C)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 4/20 0.36
SMO Q99835 1/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
SLC7A5 Q01650 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.33
SIRT1 Q96EB6 1/20 0.33
LTA4H P09960 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA14 Q9ULX7 1/20 0.33
TMPRSS6 Q8IU80 2/20 0.33
F2 P00734 1/20 0.33
CACNA1B Q00975 2/20 0.32
EPHX2 P34913 2/20 0.32
PPARG P37231 2/20 0.32
PPARA Q07869 1/20 0.32
CTSS P25774 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20168738 0.92 FOLH1 (0.46) FOLH1CA2CA9LTA4HEPHX2
SCHEMBL20179177 0.88 FOLH1 (0.37) FOLH1SMOCA2CA9SLC7A5
SCHEMBL21578146 0.88 SMO (0.35) SMOCA2CA9SLC7A5SIRT2
SCHEMBL20179259 0.86 FOLH1 (0.39) FOLH1SMOCA2CA9SLC7A5
SCHEMBL21578145 0.85 CA2 (0.33) FOLH1CA2CA9LTA4HCTSS
SCHEMBL20179137 0.82 FOLH1 (0.54) FOLH1SMOSLC7A5
SCHEMBL20179165 0.81 FOLH1 (0.58) FOLH1EPHX2PPARGPPARA
SCHEMBL20168380 0.80 FOLH1 (0.47) FOLH1CA2CA9LTA4HPPARG
SCHEMBL20168728 0.80 HTT (0.41) FOLH1CA2CA9LMNACA12
SCHEMBL20168753 0.79 CYP4F2 (0.40) FOLH1CA2CA9LTA4HLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSTY (US) 2024-01-09 US disclosed
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
WO-2018094334-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI FOLH1 39/4885SMO 3874/4885CA2 918/4885
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors TPI1, HPGDS, GPI FOLH1 39/4885SMO 3874/4885CA2 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.